Search results for: Jorge Mestre-Ferrandiz
Filter search results
Jorge Mestre-Ferrandiz Appointed Director of Consulting at OHE
12 July 2012
Jorge Mestre-Ferrandiz has been named Director of Consulting at OHE, a position newly created in response to the continuing growth of OHE Consulting. Dr. Mestre-Ferrandiz Jorge Mestre-Ferrandiz has been…
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
…Jorge Mestre-Ferrandiz from Office of Health Economics For more information contact Jorge Mestre-Ferrandiz. Jorge Mestre-Ferrandiz also presented a guest lecture at City University, London, on 17 March 2016, on the…
OHE’s Mestre-Ferrandiz has new appointment
4 May 2010
OHE is delighted to announce that Dr Jorge Mestre-Ferrandiz has been appointed an Honorary Visiting Lecturer in the Department of Economics at City University London. Dr. Mestre-Ferrandiz OHE is…
New Publication: Spillovers between Public and Private Sector Biomedical and Health Research
8 March 2016
OHE’s Yan Feng and Jorge Mestre-Ferrandiz have co-authored a new publication on quantifying the spillovers between public and private sector biomedical and health research and development funding in the UK….
Access to Orphan Drugs in the EU
21 October 2010
…determining pricing and reimbursement (P&R) also affect access. OHE’s Dr. Jorge Mestre-Ferrandiz recently presented the results of comparative research on these factors at the 9th Annual Pricing and Reimbursement Conference in…
Defining Innovation in Medicines and Transforming it into Value
3 July 2013
In June, OHE’s Jorge Mestre-Ferrandiz participated as a speaker at the Summer Course on the Evaluation of Medicines at the University of Alcalá in Spain. His presentation discussed the nature…
New Research: Achieving Efficient Prices for Drugs in a Global Context
7 February 2013
With Prof Patricia Danzon of the Wharton School, University of Pennsylvania, OHE’s Adrian Towse and Jorge Mestre-Ferrandiz have released an important working paper that addresses how to achieve efficient pricing…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
…of Prof Adrian Towse and Dr Jorge Mestre-Ferrandiz. Describing and/or forecasting the market for biosimilars must first recognize that these products are not identical, i.e., not ‘biogenerics.’ This affects both…